OncoSil Medical Ltd
OSL
Company Profile
Business description
OncoSil Medical Ltd is a medical device company. It is engaged in the development and commercialization of its product candidate, the OncoSil localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma. It operates in one segment. the device development for new medical treatments. Geographically, the company derives its maximum revenue from Europe and the rest from Australia and New Zealand.
Contact
7 Eden Park Drive
Level 5
Macquarie Park
SydneyNSW2113
AUST: +61 289359629
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
30 June 2027
Employees
2
Stocks News & Analysis
stocks
Pure-play data center share raises capital to fund AI demand
Funding the next wave of data center growth.
stocks
Chart of the Week: BHP’s growth story faces a reality check
China’s slowing economy could weigh on BHP’s future growth.
stocks
3 best ASX growth stocks to buy for the long term
Here’s three high-quality growth companies with wide moats.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,978.80 | 34.20 | -0.38% |
| CAC 40 | 8,377.86 | 4.57 | -0.05% |
| DAX 40 | 24,915.49 | 84.04 | -0.34% |
| Dow JONES (US) | 52,552.97 | 105.67 | -0.20% |
| FTSE 100 | 10,574.69 | 2.45 | 0.02% |
| HKSE | 24,504.21 | 504.39 | -2.02% |
| NASDAQ | 25,881.95 | 387.28 | -1.47% |
| Nikkei 225 | 64,141.12 | 2,694.42 | -4.03% |
| NZX 50 Index | 13,694.68 | 79.90 | 0.59% |
| S&P 500 | 7,533.77 | 38.63 | -0.51% |
| S&P/ASX 200 | 8,796.70 | 20.10 | -0.23% |
| SSE Composite Index | 3,764.63 | 117.78 | -3.03% |